 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 GLOBE NEWSWIRE -- VistaGen Therapeutics, Inc. NASDAQ: VTGN, a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system CNS disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value 0.001 per share the Common Stock, and its Series D convertible preferred stock the Series D Preferred Stock. All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 